Key result
Accumulating data suggest a potential role for daily aspirin in colorectal cancer prevention, though questions remain regarding its mechanism, dose-dependency, and bleeding risks.
Why the study?
Does daily aspirin use prevent colorectal cancer and outweigh the harm from aspirin-induced bleeding in the general population?
Does daily aspirin use prevent colorectal cancer and outweigh the harm from aspirin-induced bleeding in the general population?
The text highlights key unanswered questions regarding the prophylactic use of daily aspirin for colorectal cancer prevention, including mechanisms, dose-dependence, and bleeding risks.
Answers are grounded in this paper and cite their sources.
Daily aspirin for colorectal cancer prevention should not yet change practice; leaves open dosing, mechanisms, and net benefit versus bleeding.
The accumulating data from randomized clinical trials provide the rational to consider the potential role of daily aspirin use in colorectal cancer (CRC) prevention, and possibly other types of cancer (Thun et al., 2012). However, some questions require to be addressed before the recommendation for the prophylactic use of aspirin in the population: (i) what is the mechanism of the anti-tumorigenic effect of aspirin?; (ii) is the chemopreventive effect dose-dependent?; (iii) may daily low-dose aspirin affect other types of cancers in addition to CRC?; (iv) does the reduced risk of colorectal cancer by daily aspirin outweigh harm from aspirin-induced bleeding?
No takes yet. Share an insight, caveat, or question.
Patrignani et al. (2015) conducted a review in Colorectal cancer (CRC). Aspirin was evaluated. Accumulating data suggest a potential role for daily aspirin in colorectal cancer prevention, though questions remain regarding its mechanism, dose-dependency, and bleeding risks.
Synapse has enriched 10 related papers. Consider them for comparative context: